Werner Baumann, Bayer CEO (Sascha Steinbach/picture-alliance/dpa/AP Images)

Bay­er cuts four pro­grams amid a 's­low start' to the year

Bay­er an­nounced a hand­ful of pipeline cuts in its quar­ter­ly earn­ings re­port last week, as CEO Wern­er Bau­mann re­vealed the quar­ter “came in soft” com­pared to last year’s per­for­mance.

The culls in­clude two Phase II pro­grams, a BD­KRB1 re­cep­tor an­tag­o­nist for neu­ro­path­ic pain, and run­caciguat, in de­vel­op­ment for chron­ic kid­ney dis­ease. The BD­KRB1 re­cep­tor plays a role in pain per­cep­tion, and Bay­er’s can­di­date, BAY 2395840, came out of a re­search al­liance with Evotec. The com­pa­ny al­so said it’s dis­con­tin­u­ing a Phase I pro­gram study­ing BAY 2395840 in en­dometrio­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.